Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CYMABAY THERAPEUTICS, INC.

(CBAY)
  Rapport
Vertraagde tijd Nasdaq  -  19:00 25-11-2022
3.300 USD   -0.30%
16/11CymaBay Therapeutics, Inc. : Een koopadvies van Oppenheimer
MM
14/11CymaBay Therapeutics, Inc. Rapporteert winstresultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2022
CI
14/11Earnings Reaction History: CymaBay Therapeutics Inc, 50,0% opvolgingsindicator, 17,2% gevoelig
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť CYMABAY THERAPEUTICS, INC.
14/11CYMABAY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
14/11CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Result..
AQ
07/11CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, Novem..
AQ
07/11CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar f..
AQ
04/11CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar f..
AQ
03/11CymaBay Therapeutics to Present at Upcoming Investment Conferences
AQ
02/11CymaBay Announces Appointment of Charles McWherter Ph.D. to Chief Scientific Officer an..
AQ
01/11CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer a..
AQ
01/11Cymabay Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
04/10CymaBay Therapeutics Announces Three Presentations at the Liver Meeting 2022
AQ
03/10CymaBay Therapeutics Announces Three Presentations at The Liver Meetingģ 2022
AQ
14/09CymaBay Therapeutics Hosting Virtual Analyst Day on September 22
AQ
06/09CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Co..
AQ
25/08CymaBay Therapeutics to Participate in B. Riley's Mini PBC Symposium on August 24, 2022
AQ
24/08CymaBay Therapeutics to Participate in B. Riley's Mini PBC Symposium on August 24, 2022
AQ
11/08CYMABAY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
11/08CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and..
AQ
04/08CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, Au..
AQ
01/08CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpa..
AQ
23/06CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress 202..
AQ
22/06CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress&tra..
AQ
14/06Cymabay Therapeutics, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K..
AQ
09/06CymaBay Therapeutics Announces Presentations During The International Liver Congress 20..
AQ
08/06CymaBay Therapeutics Announces Presentations During The International Liver Congress&tr..
AQ
23/05CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients fo..
AQ
12/05CYMABAY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
12/05CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update
AQ
11/05CymaBay Therapeutics Announces Presentations at Digestive Disease Weekģ 2022
AQ
05/05CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May..
AQ
19/04CYMABAY THERAPEUTICS, INC. Change in Directors or Principal Officers (form 8-K/A)
AQ
04/04CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase..
AQ
18/03CymaBay Announces Appointment of Eric Lefebvre, M.D. to Board of Directors
AQ
17/03Cymabay Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
17/03CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors
AQ
17/03CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and P..
AQ
17/03CYMABAY THERAPEUTICS, INC. . Management ' s Discussion and Analysis of Financial Cond..
AQ
10/03CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on T..
AQ
10/02CymaBay Therapeutics to Present at Upcoming Investor Conferences
AQ
2021Cymabay Therapeutics, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
AQ
2021CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GL
2021CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two..
AQ
2021CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Pr..
AQ
2021CYMABAY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
2021CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Result..
GL
2021CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Result..
GL
2021CymaBay Therapeutics to Present at Upcoming Investor Conferences
AQ
2021CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, Novem..
GL
2021Cymabay Therapeutics : Announces Presentations at The Liver Meeting 2021
AQ
2021Cymabay Therapeutics : Announces Presentations at The Liver Meetingģ 2021
AQ
2021Cymabay Therapeutics : to Present at Upcoming Investor Conferences
AQ
2021Cymabay Therapeutics : Reports Second Quarter and Six Months Ended June 30, 2021 Financial..
AQ
2021Cymabay Therapeutics : Management's Discussion and Analysis of Financial Condition and Res..
AQ
2021CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, Augus..
GL
2021Cymabay Therapeutics, Inc. : Entry into a Material Definitive Agreement, Creation of a Dir..
AQ
2021Cymabay Therapeutics : Announces $100 Million Non-Dilutive Financing with Abingworth
AQ
2021Cymabay Therapeutics : Presents Positive PBC Data at the International Liver Congress 2021
AQ
2021Cymabay Therapeutics : Presents Positive PBC Data at the International Liver Congress&trad..
AQ
2021Cymabay Therapeutics, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K..
AQ
2021CymaBay Therapeutics to Present at Upcoming Investor Conferences
GL
2021Cymabay Therapeutics : Announces Presentations During The International Liver Congress&tra..
AQ
2021Cymabay Therapeutics : Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
2021Cymabay Therapeutics : Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
2021CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update
GL
2021Cymabay Therapeutics : Management's Discussion and Analysis of Financial Condition and Res..
AQ
2021Cymabay Therapeutics : Welcomes Dennis D. Kim, MD, MBA as Chief Medical Officer
AQ
2021Cymabay Therapeutics : Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
2021Cymabay Therapeutics : Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
2021CymaBay Names Lewis Stuart Chief Commercial Officer
GL
2021CymaBay Therapeutics to Report First Quarter 2021 Financial Results on Thursday, May 13..
GL
2021Cymabay Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Cymabay Therapeutics : Appoints Thomas Wiggans and Janet Dorling to Board of Directors
AQ
2021Cymabay Therapeutics : Management (form 10-K)
AQ
2021CymaBay Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corpora..
GL
2021Cymabay Therapeutics : to Report Fourth Quarter and Full Year 2020 Financial Results on Th..
AQ
1  2  3  4Volgende
Volgende evenement op CYMABAY THERAPEUTICS, INC.